Anil Gogineni, MD
Pulmonary Disease · Ocala, FLNPI 1821267386
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,274 of the $147,426 with a category attached, or 83.6%. 45 manufacturers reported payments, led by GSK at 43.0% of the total. Reporting peaked in 2023 at $33,538 and has fallen 86.3% since, to $4,602 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 678 payments — averaging $217.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$63K
- Boehringer Ingelheim$30K
- Grifols USA, LLC$22K
- Mylan Specialty L.p.$13K
- Sunovion Pharmaceuticals Inc.$9K
- AstraZeneca$2K
- plus $9K from 39 others
What the payments were for
- Consulting fees$2,8082%
- Speaking & faculty fees$123,27484%
- Travel & lodging$4,3223%
- Food & beverage$16,56611%
- Education$4560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$19,989
- Prolastin-C Liquid$19,385
- Yupelri$12,179
- OFEV$10,304
- LONHALA MAGNAIR$8,772
- Prolastin-C$2,371
- Da Vinci Surgical System$1,251
- BREZTRI$711
- DUPIXENT$536
- XARELTO$492
- Impella$385
- UPTRAVI$274
- OPSUMIT$274
- NUCALA$239
- FASENRA$229
- TEZSPIRE$229
- Wakix$125
- AREXVY$125
- FARXIGA$121
- DSUVIA$120
How this compares
$147,426 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 29 | $453,672 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 245 | $270,090 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 21 | $187,906 |
| Dupixent PenDupilumab | 40 | $145,799 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $125,513 |
| NucalaMepolizumab | 19 | $68,909 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $65,061 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $48,433 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $39,324 |
| Spiriva RespimatTiotropium Bromide | 38 | $37,912 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $23,502 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 492 | $17,163 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $15,569 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 53 | $10,404 |
| DuleraMometasone/Formoterol | 21 | $9,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $29,953 | $563,520131 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $63,363 | $443,384426 claims |
| Grifols USA, LLCProlastin C | $22,188 | $187,90621 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,767 | $141,083145 claims |
| MerckDulera | $119 | $9,78721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Ocala
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.